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Background: Identification of novel genetic risk factors is imperative for a better understanding of B lymphomagenesis
and for the development of novel therapeutic strategies. TRAF3, a critical regulator of B cell survival, was recently
recognized as a tumor suppressor gene in B lymphocytes. The present study aimed to identify novel oncogenes
involved in malignant transformation of TRAF3-deficient B cells.
Methods: We used microarray analysis to identify genes differentially expressed in TRAF3−/− mouse splenic B
lymphomas. We employed lentiviral vector-mediated knockdown or overexpression to manipulate gene expression in
human multiple myeloma (MM) cell lines. We analyzed cell apoptosis and proliferation using flow cytometry, and
performed biochemical studies to investigate signaling mechanisms. To delineate protein-protein interactions, we
applied affinity purification followed by mass spectrometry-based sequencing.
Results: We identified mutated in colorectal cancer (MCC) as a gene strikingly up-regulated in TRAF3-deficient mouse B
lymphomas and human MM cell lines. Aberrant up-regulation of MCC also occurs in a variety of primary human B cell
malignancies, including non-Hodgkin lymphoma (NHL) and MM. In contrast, MCC expression was not detected in
normal or premalignant TRAF3−/− B cells even after treatment with B cell stimuli, suggesting that aberrant up-regulation
of MCC is specifically associated with malignant transformation of B cells. In elucidating the functional roles of MCC in
malignant B cells, we found that lentiviral shRNA vector-mediated knockdown of MCC induced apoptosis and inhibited
proliferation in human MM cells. Experiments of knockdown and overexpression of MCC allowed us to identify several
downstream targets of MCC in human MM cells, including phospho-ERK, c-Myc, p27, cyclin B1, Mcl-1, caspases 8 and 3.
Furthermore, we identified 365 proteins (including 326 novel MCC-interactors) in the MCC interactome, among which
PARP1 and PHB2 were two hubs of MCC signaling pathways in human MM cells.
Conclusions: Our results indicate that in sharp contrast to its tumor suppressive role in colorectal cancer, MCC
functions as an oncogene in B cells. Our findings suggest that MCC may serve as a diagnostic marker and therapeutic
target in B cell malignancies, including NHL and MM.
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B cell neoplasms account for over 90% of lymphoid tu-
mors worldwide, and comprise >50% of blood cancers.
Despite recent advances in treatment, many types of hu-
man B cell lymphomas remain incurable, highlighting a
clear need for new preventative and therapeutic strat-
egies [1,2]. Increasing evidence indicates the importance* Correspondence: xiep@rci.rutgers.edu
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Identification and validation of new genetic risk factors
are imperative for a better understanding of B cell malig-
nant transformation and for the development of new
therapeutic strategies. Recent studies from our labora-
tory and others have identified TRAF3, a critical deter-
minant of B cell survival, as a tumor suppressor gene in
B lymphocytes. TRAF3 is a member of the tumor necro-
sis factor receptor (TNF-R)-associated factor (TRAF)
family (TRAF1-6) of cytoplasmic adaptor proteins [6].
All TRAF proteins have the distinctive feature of a C-l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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with TRAF-binding motifs of receptors of the TNF-R
superfamily [6,7]. Homozygous deletions and inactivat-
ing mutations of the TRAF3 gene have been identified in
non-Hodgkin lymphoma (NHL), including splenic mar-
ginal zone lymphoma (MZL), B cell chronic lymphocytic
leukemia (B-CLL) and mantle cell lymphoma (MCL), as
well as multiple myeloma (MM) and Waldenström’s
macroglobulinemia (WM) [8-11].
By generating and characterizing a mouse model that
has the Traf3 gene specifically deleted in B lymphocytes
(B-TRAF3−/− mice), we recently reported that TRAF3
deletion leads to spontaneous development of MZL and
B1 lymphoma in mice [12,13]. Interestingly however, B
lymphoma development in B-TRAF3−/− mice exhibits a
long latency (approximately 9 months), indicating that
TRAF3 inactivation and its aberrant signaling pathways
are not sufficient to induce B lymphomagenesis and that
additional oncogenic pathways are necessary for B lym-
phoma development. Although TRAF3 deletions or mu-
tations exist in human patients with NHL and MM, it is
not known whether TRAF3 inactivation is the primary
or secondary oncogenic mutation in human samples.
Thus, B-TRAF3−/− mice offer the unique advantage to
identify secondary oncogenic pathways that drive B lym-
phomagenesis in the context of TRAF3 inactivation. To
identify such secondary oncogenic alterations that medi-
ate the malignant transformation of TRAF3−/− B cells,
we performed a transcriptome microarray analysis using
TRAF3−/− mouse splenic B lymphomas. Surprisingly, our
microarray analysis identified mutated in colorectal cancer
(MCC), a tumor suppressor gene of colorectal cancer, as a
strikingly up-regulated gene in B lymphomas spontan-
eously developed in different individual B-TRAF3−/− mice.
The MCC gene was discovered in 1991 through its
linkage to the region showing loss of heterozygosity
(LOH) in familial adenomatous polyposis (FAP) [14-17].
Subsequent studies revealed that the adenomatous
polyposis coli (APC) gene and not MCC is responsible
for FAP. The APC gene is mutated somatically in 60–
80% of sporadic colorectal cancers (CRCs), whereas
somatic mutation of MCC is relatively rare, 3–7%, in
sporadic CRCs [14-18]. However, it was subsequently re-
ported that the MCC gene is silenced through promoter
methylation in approximately 50% of primary sporadic
CRCs and 80% of serrated polyps, suggesting that the
silencing of MCC is important in early colon carcinogen-
esis via the serrated neoplasia pathway [19-22]. Further-
more, loss-of-function mutations, LOH, or decreased
expression of theMCC gene are also detected in a number
of other human cancers, including lung cancer [17,23],
gastric carcinoma [24], esophageal cancer [25], and hepa-
tocellular carcinoma [26,27]. In addition, an SNP of the
MCC gene (rs11283943) is significantly associated withincreased risk of breast cancer [28]. Although an inactivat-
ing MCC mutation in mice alone failed to induce any evi-
dent CRCs, the homozygous mice displayed a slightly
higher proliferation rate of the epithelial crypt cells
[29,30]. Interestingly, an unbiased genetic screening of a
mouse model of CRC implicated MCC mutation as a key
event in colorectal carcinogenesis [18]. Consistent with
the genetic evidence, functional studies revealed that
MCC blocks cell cycle progression in NIH3T3 fibroblasts
and CRCs [31,32], inhibits cell proliferation and migration
in CRCs [20,32-34], and is required for DNA damage re-
sponse in CRCs [35]. MCC appears to specifically target
and negatively regulate the oncogenic NF-κB and β-
catenin pathways in CRCs and hepatocellular carcinoma
[20,27,32,36]. Mutation studies have revealed that the N-
terminal domain (130–278 aa) of MCC is required for
repressing the Wnt/β-catenin signaling pathway [20] and
that the PDZ-binding motif at the extreme C-terminus of
MCC mediates its interaction with Scrib-Myosin IIB to
regulate cytoskeletal reorganization and cell migration in
CRCs [34]. Collectively, the above genetic and functional
evidence indicates that MCC functions as a tumor sup-
pressor gene in CRCs by inhibiting cell cycle progression
and migration, and by promoting DNA damage-induced
cell cycle arrest in colorectal epithelial cells.
It has been shown that during development, MCC is
expressed in diverse tissues derived from all three em-
bryonic germ layers, including the developing gut and
central nervous system [29]. In adults, MCC is expressed
in the surface epithelium of the colon and villi of the
small intestines as well as other tissues, including the
cerebellar cortex, kidney, pancreas, and liver [31,37].
However, expression of MCC was not reported in lym-
phocytes, and the function of MCC in lymphocytes or
lymphomas has not been explored. In the present study,
we aimed to address this gap in knowledge.
Our unexpected finding that MCC was strikingly up-
regulated in TRAF3−/− mouse B lymphomas prompted
us to further examine MCC expression in human B cell
neoplasms. Our results demonstrated high levels of aber-
rant MCC expression in 6 human patient-derived MM
cell lines with TRAF3 deletions or relevant mutations.
We also surveyed the public gene expression database of
microarray data of human cancers (http://www.oncomine.
org), and learned that MCC was also aberrantly and sig-
nificantly elevated in a variety of primary human B cell
malignancies. These include primary effusion lymphoma
(PEL), centroblastic lymphoma (CBL), diffuse large B-cell
lymphoma (DLBCL), Burkitt’s lymphoma (BL), and MM
[38-41]. However, expression of the transcript and protein
of MCC was not detected in wild type B cells or premalig-
nant TRAF3−/− B cells, even after treatment with a variety
of B cell stimuli, including CD40, BCR, LPS, and CpG.
These results suggest that aberrant MCC expression is
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investigated the functions of MCC in malignant B cell sur-
vival and proliferation, and found that lentiviral shRNA
vector-mediated knockdown of MCC induced apoptosis
and inhibited proliferation in human patient-derived MM
cell lines. Furthermore, we identified MCC signaling
pathways and interacting partners in malignant B cells.
Our results thus provide novel mechanistic insights into
how MCC promotes malignant B cell survival and pro-
liferation. Taken together, our findings indicate that in
sharp contrast to its tumor suppressive function in
CRCs and other human carcinomas, MCC is oncogenic
in B lymphocytes.
Results
Transcriptome microarray analysis of TRAF3-/- mouse
B lymphomas
TRAF3−/− B cells purified from young B-TRAF3−/− mice
exhibit prolonged survival but do not proliferate autono-
mously [12], and therefore are premalignant B cells.
Consistent with this, no B lymphoma development was
observed in B-TRAF3−/− mice younger than 9 months
old [13]. The long latency of B lymphoma development
observed in B-TRAF3−/− mice suggests that TRAF3 in-
activation and its downstream signaling pathways are
not sufficient and that additional oncogenic alterations
are required to induce B lymphomagenesis. To identify
such secondary oncogenic alterations, to provide new in-
sights into the molecular mechanisms of B cell malig-
nant transformation, and to discover new therapeutic
targets for the treatment of B cell malignancies, we per-
formed global gene expression profiling of TRAF3−/−
mouse B lymphomas by transcriptome microarray
analysis. We used RNA samples of 3 representative
TRAF3−/− splenic B lymphomas (mouse ID: 6983–2,
7041–10, and 7060–8), in which B lymphomas are >70%
of B cells, as assessed by FACS analysis of B cell popula-
tions and Southern blot analysis of IgH gene rearrange-
ments [13]. Results of the microarray analysis have
identified 160 up-regulated genes and 244 down-regulated
genes in TRAF3−/− B lymphomas as compared to LMC
spleens (cut-off fold of changes: 2-fold up or down, p <
0.05; Additional file 1: Table S1) (NCBI GEO accession
number: GSE48818). Selective examples of these identified
genes are shown in the heatmap (Figure 1A). Functional
clustering and pathway analyses by Ingenuity (http://www.
ingenuity.com) revealed that genes differentially expressed
in TRAF3−/− B lymphomas include transcription factors,
cell surface receptors, enzymes, cell cycle regulators, pro-
tein translation regulators, lipid metabolism regulators,
and novel genes with unknown functions.
From the genes identified by the microarray analysis,
we selected 12 genes up-regulated in TRAF3−/− B lymph-
omas for further verification by quantitative real time PCRusing TaqMan gene expression assay kits. Our data veri-
fied the mRNA up-regulation of the 12 genes examined,
including Diras2, MCC,Tbc1d9, Ccbp2, Btbd14a, Sema7a,
Twsg1, Ppap2b, TCF4, Tnfrsf19, Zcwpw1, and Abca3
(Figure 1B). Striking up-regulation of these transcripts was
verified in the three splenic B lymphoma samples used for
microarray analyses (mouse ID: 6983–2, 7041–10, and
7060–8), and also confirmed in three additional splenic B
lymphomas (mouse ID: 7140–7, 7140–3 and 5–5) as well
as ascites from two cases (mouse ID: 7060–8 and 7140–3;
Figure 1B). Thus, up-regulation of these 12 genes is recur-
rent in B lymphomas spontaneously developed in different
individual B-TRAF3−/− mice.
We next surveyed public gene expression databases of
human cancers (http://www.oncomine.org) [42] and
searched the literature to investigate whether the genes
identified in our microarray analyses exhibit alterations
in mRNA expression, DNA copy number variation, or
mutations in primary human B lymphomas and other
cancers. Interestingly, we found that among the up-
regulated genes identified in our microarray analysis,
MCC is most consistently up-regulated in a variety of
primary human B cell malignancies, including PEL, CBL,
DLBCL, BL, and MM [38-41]. It has been previously
shown that MCC functions as a tumor suppressor gene
in CRCs and hepatocellular carcinoma [20,27,31-35].
However, the functional roles of MCC in lymphocytes or
lymphomas remain unknown. In this context, we se-
lected to further explore the expression and function of
MCC in B lymphocytes and B cell malignancies in the
present study.
Striking up-regulation of MCC in TRAF3-/- mouse B
lymphomas but not in premalignant TRAF3-/- B lymphocytes
We first verified the up-regulation of MCC in splenic B
lymphomas and ascites spontaneously developed in 8
different individual B-TRAF3−/− mice at the protein level
using Western blot analysis (Figure 2A). In contrast,
MCC protein expression was not detected in LMC
splenic B cells (Figure 2A). We also compared the tran-
script expression of MCC in different mature B cell sub-
sets or B cells of different developmental stages by
surveying the public gene expression database of Mouse
Immune Genome (http://www.immgen.org). Mature B
cell subsets examined include follicular, marginal zone,
germinal center, and B1 B cells, and developing B cells
examined include common lymphoid progenitor, pre-
pro-B, pro-B, pre-B, newly-formed B, and transitional
(T1, T2 and T3) B cells. The data in Mouse Immune
Genome indicate that the MCC transcript is barely de-
tected in any mature B cell subsets or developing B cells
of any developmental stages. It has been previously
shown that the expression of MCC is gradually up-
regulated during differentiation of PC12 cells induced by

























































































































































































































































































































































































Figure 1 (See legend on next page.)
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Figure 1 Representative genes differentially expressed in TRAF3−/− mouse B lymphomas identified by the transcriptome microarray
analysis. (A) Heatmap of representative microarray data. The mRNA expression profiles of splenocytes from 3 pairs of LMC and tumor-bearing
B-TRAF3−/− mice were analyzed by microarray analysis. cRNA was hybridized to the Illumina Sentrix MouseRef-8 24 K Array (Illumina). Genes
shown in the heatmap are selected from 160 up-regulated and 244 down-regulated genes: red indicates overexpression, blue indicates
underexpression, and black indicates median expression. Values under the color key indicates Log2 (fold of change). Dendrogram on top of the
heatmap shows the relatedness between samples as determined by hierarchical clustering. (B) Verification of transcript up-regulation of genes
identified by the microarray analysis using quantitative real time PCR. Total cellular RNA was prepared from splenocytes of LMC mice, or splenic B
lymphomas (spl) and ascites (asc) of diseased B-TRAF3−/− mice, and cDNA was synthesized by reverse transcription. Real time PCR was performed
using TaqMan primers and probes (FAM-labeled) specific for mouse Diras2, MCC, Tbc1d9, Ccbp2, Btbd14a, Sema7a, Twsg1, Ppap2b, TCF4, Tnfrsf19,
Zcwpw1, and Abca3. Each reaction also included the probe (VIC-labeled) and primers for mouse β-actin mRNA, which served as endogenous
control. Relative mRNA expression levels of each gene were analyzed using the Sequencing Detection Software (Applied Biosystems) and the
comparative Ct (ΔΔCt) method. Graphs depict the results of two experiments with duplicate reactions in each experiment (mean ± S.D.), and
mouse ID of each sample is indicated in the graphs.
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regulation of MCC during the proliferation, differenti-
ation, and activation of B lymphocytes induced by a
variety of B cell stimuli. We purified splenic B cells from
LMC or tumor-free young B-TRAF3-/- mice (age: 10–12
weeks; premalignant TRAF3−/− splenic B cells), and then
stimulated the cells with various B cell stimuli. These in-
clude agonistic anti-CD40 Abs, LPS (TLR4 agonist), B
cell receptor (BCR) crosslinking Abs, and CpG2084
(TLR9 agonist), alone or in combination. TLR4 and TLR9
were examined as a representative of plasma membrane-
and endosome- localized members of the TLR family, re-
spectively [43]. We found that the transcript of MCC was
neither up-regulated nor detected in LMC or premalig-
nant TRAF3−/− splenic B cells after treatment with any of
the stimuli examined (Figure 2B). In contrast, the expres-
sion of Zcwpw1, another gene identified by our microarray
analysis, was robustly up-regulated in LMC or premalig-
nant TRAF3−/− splenic B cells after treatment with LPS
alone, LPS in combination with CD40, or CpG in combin-
ation with CD40. This indicates that expression of
Zcwpw1 is induced during the proliferation and activation
of B lymphocytes. However, unlike Zcwpw1, the ex-
pression of MCC is only up-regulated and detected in
TRAF3−/− B lymphomas, suggesting that MCC up-
regulation is selectively associated with B cell malignant
transformation.
We next cloned the full-length coding sequence of the
MCC transcripts from primary splenic B lymphomas of
4 different individual B-TRAF3−/− mice (mouse ID:
6983–2, 7060–8, 105–8, and 115–6) by reverse tran-
scription and PCR. Our sequencing results demonstrated
that the MCC gene expressed in TRAF3−/− B lymph-
omas is predicted to encode a protein of 828 amino
acids and does not contain any mutations. In an effort to
understand how MCC is up-regulated in TRAF3−/− B
lymphomas, we first determined the copy number of the
MCC gene in primary splenic B lymphomas of 8 differ-
ent individual B-TRAF3−/− mice using Taqman Copy
Number Assay Kit. Our results revealed that the copynumber of the MCC gene was not changed in TRAF3−/−
mouse B lymphomas as compared to that observed in
LMC splenocytes (Figure 2C). We next investigated the
involvement of epigenetic alterations in MCC up-
regulation by performing chromatin immunoprecipita-
tion (ChIP) analyses. We used antibodies specific for a
repressive histone mark (trimethylated Lys 27 of histone
3, H3K27Me3) and an activating histone mark (acety-
lated Lys 9/14 of histone 3, H3K9/14Ac), respectively.
We chose to examine these two epigenetic modifications
based on previous evidence that alterations of H3K27Me3
and H3K9/14Ac frequently occur in human B lymphomas
and MM [44-51]. Our results showed that the activating
H3K9/14 acetylation of the promoter region of the MCC
gene was not obviously changed in TRAF3−/− B lymphoma
cells as compared to LMC or premalignant TRAF3−/−
splenic B cells (Figure 2D). In contrast, the repressive
H3K27 trimethylation of the MCC promoter region was
almost completely abolished in TRAF3−/− B lymphoma
cells, and also modestly decreased in premalignant
TRAF3−/− splenic B cells (Figure 2D). Such changes in
H3K27 trimethylation was not observed in the promoter
region of Diras2 (Figure 2D), another gene strikingly
up-regulated in TRAF3−/− B lymphomas identified in
our study. The trimethylation of H3K27 that is almost
completely abolished in the MCC promoter region in
TRAF3−/− B lymphomas is intriguing, considering that
the expression levels and activity of EZH2 of the poly-
comb repressive complex 2 (PRC2) catalyzing H3K27Me3
are often elevated in human B lymphomas and MM
[45-47]. This unexpected decrease of the repressive
H3K27Me3 of the MCC promoter region may be caused
by increased activity of the H3K27 demethylase UTX or
altered recognition of the MCC promoter by PRC2 in
TRAF3−/− B lymphoma cells. Altered recognition of the
MCC promoter by PRC2 might be brought about by
changes in DNA methylation of this region, accessory pro-
teins of the PRC2 complex, or expression of EZH2-
binding non-coding RNA surrounding the MCC gene
locus in TRAF3−/− B lymphomas [47,52-54]. Regardless
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Figure 2 (See legend on next page.)
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Figure 2 Striking up-regulation of MCC in TRAF3-/- mouse B lymphomas but not in premalignant TRAF3-/- B lymphocytes. (A) Western
blot analysis of the MCC protein. Total cellular proteins were prepared from purified LMC splenic B cells or splenic B lymphomas (spl) or ascites
(asc) of different individual B-TRAF3−/− mice. (B) Regulation of the expression of MCC and Zcwpw1 in response to B cell stimuli. LMC and
premalignant (young) TRAF3-/- splenic B cells were cultured ex vivo in the absence or presence of stimuli of B cell proliferation, differentiation and
activation for 6 or 24 hours. B cell stimuli examined include: 2 μg/ml anti-CD40, 20 μg/ml LPS, 1 μg/ml anti-BCR, and 100 nM CpG2084, alone or
in combination. RNA samples of TRAF3-/- B lymphomas (mouse ID: 7060–8) were used as positive control of the MCC and Zcwpw1 transcripts in
Taqman assays. (C) Normal copy number of the MCC gene in TRAF3-/- mouse B lymphomas. Copy number of the mouse MCC gene in genomic
DNA samples prepared from LMC splenocytes or TRAF3−/− B lymphomas was determined using the TaqMan Copy Number Assay kit. Mouse ID
was indicated in the figure. (D) Histone modifications of the promoter region of the MCC and Diras2 genes. Chromatin was prepared from LMC
and young TRAF3-/- splenic B cells, or TRAF3-/- B lymphomas. Fragmented chromatin was immunoprecipitated using antibodies specific for
histone marks (H3K27me3 or H3K9/14ac) or non-specific rabbit Ig. Immunoprecipitated DNA was quantified by qPCR using primer pairs specific
for the promoter region of the MCC and Diras2 genes, respectively. Quantity of immunoprecipitated DNA is presented as percentage of input
DNA in graphs. All graphs (B-D) depict the results of three independent experiments with duplicate reactions in each experiment (mean ± S.D.).
*P < 0.05, and **P < 0.0001 by Student’s t test.
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ations in epigenetic modifications (such as H3K27Me3)
of the MCC promoter region contribute at least partially
to the up-regulation of MCC observed in TRAF3−/−
B lymphomas.
Aberrant up-regulation of MCC in human patient-derived
MM cell lines with TRAF3 deletions or relevant mutations
To confirm the clinical relevance of our study, we exam-
ined MCC expression in 6 human patient-derived MM
cell lines with TRAF3 deletions or relevant mutations.
These include: two cell lines with TRAF3 bi-allelic dele-
tions (KMS11 and 8226), two cell lines with TRAF3
frameshift mutations (LP1 and U266), and two cell lines
with cIAP1/2 bi-allelic deletions (KMS28PE and KMS20).
Similar to TRAF3 inactivation, bi-allelic deletions of
cIAP1/2 also lead to constitutive activation of the non-
canonical NF-κB pathway, NF-κB2 (p52/RelB) [9]. We
found that MCC is aberrantly up-regulated in all examined
human MM cell lines at both the transcript and protein
levels (Figure 3A and B). Robust expression of MCC was
also detected in an EBV-transformed B lymphoblastoid cell
line C3688 [55], which also exhibits constitutive NF-κB2
activation. In contrast, MCC expression was not detected
in normal human blood B lymphocytes. It should be noted
that MM is the tumor of terminally differentiated B cells,
plasma cells. By directly comparing with purified normal
plasma cells, microarray analyses by Zhan et al. have previ-
ously identified aberrant up-regulation of the MCC tran-
script in MM patient samples [39,40]. Similarly, microarray
analyses by Basso et al. have demonstrated aberrant up-
regulation of the MCC transcript in patient samples of B
lymphomas (PEL, CBL, BL and DLBCL) as compared
with normal B cells of different activation stages, in-
cluding naive pre-germinal center B cells, centroblasts,
centrocytes, and memory B cells [38]. Together, the
above evidence indicates that MCC is aberrantly up-
regulated only in malignant B cells and neoplastic
plasma cells, but not in their normal counterparts.We then cloned the full-length coding sequence of the
MCC transcripts from LP1 and KMS11 cells by reverse
transcription and PCR. Sequencing results of the PCR
products of MCC transcripts demonstrated that the cod-
ing cDNAs of the MCC gene cloned from human MM
cells are predicted to encode a protein of 829 amino
acids and contain no mutations. Our results thus dem-
onstrate that MCC is aberrantly expressed in both
mouse and human transformed B cells, but not ex-
pressed in normal B lymphocytes.
Subcellular localization of MCC and its regulation in
human MM cells during ER stress responses
Subcellular localization of a protein provides important
clues about its potential function. It has been previously
shown that MCC is localized in the cytosol as well as in
the nucleus, and is also associated with the plasma
membrane and membrane organelles in epithelial cells
[20,31,33,37]. To elucidate where MCC exerts its roles
in malignant B cells, we examined the subcellular
localization of MCC using a biochemical fractionation
method. To investigate whether MCC protein level is
regulated in response to apoptosis induction and ER
stress, we employed two ER stress inducers, DTT (a
chemical that reduces disulfides to thiols and thus af-
fects protein folding or conformation) and thapsigargin
(an inhibitor of ER Ca2+ transport). We prepared the
cytosol, microsomes (rich in ER), mitochondria and nu-
clei fractions from human MM cells in the absence or
presence of treatment with DTT or thapsigargin. Our re-
sults revealed that MCC protein was primarily localized
in the mitochondria, but also detectable in the ER, cyto-
sol and nucleus in human MM cells (Figure 3C). Inter-
estingly, we noticed that the two ER stress inducers,
DTT and thapsigargin, markedly inhibited the protein
levels of MCC, but did not change the subcellular
localization of MCC in human MM cells (Figure 3C).
The ER stress responses induced by DTT and thapsigar-














































































































































Figure 3 Aberrant expression and subcellular localization of MCC in human MM cells. (A) Taqman assay of the MCC transcript. Total
cellular RNA was prepared from normal human blood B lymphocytes (Normal B), an EBV-transformed B lymphoblastoid cell line C3688, or human
MM cell lines with TRAF3 deletions or relevant mutations. The human MM cell lines include KMS11, 8226, LP1, U266, KMS28PE, and KMS20.
Real-time PCR was performed using TaqMan primers and probes (FAM-labeled) specific for human MCC. Each reaction also included the probe
(VIC-labeled) and primers for human β-actin mRNA, which served as an endogenous control. Relative mRNA expression levels of the MCC gene were
analyzed using the Sequencing Detection Software (Applied Biosystems) and the comparative Ct (ΔΔCt) method. Graphs depict the results of three
independent experiments with duplicate reactions in each experiment (mean ± S.D.). (B) Western blot analysis of the MCC protein. Total cellular
proteins were prepared from normal B lymphocytes, C3688 cells, or human MM cell lines with TRAF3 deletions or relevant mutations. Proteins were
immunoblotted for MCC, followed by TRAF3 and actin. Data shown are representative of 3 experiments. (C) Subcellular localization of MCC and its
regulation during ER stress responses. LP1 cells were cultured in the absence (control) or presence of ER stress inducers DTT or thapsigargin (Thg). After
treatment for 24 hours, cytosol (S100), ER, mitochondria (mito) and nuclei (Nuc) were biochemically fractionated from cells, and an aliquot of cells was
used for total protein lysates (Total). Proteins in each fraction or total lysates were immunoblotted for MCC, Rhbdf1 (an ER protein), cIAP1, cIAP2, cyclin
D2, COX IV (a mitochondrial protein), and actin. Results shown are representative of 3 independent experiments.
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of apoptosis in human MM cells (Figure 3C and data
not shown). Yang et al. have previously shown that
cIAP2 is cleaved by the mitochondrial serine protease
Omi/HtrA2 during apoptosis [56]. Given the predominantmitochondrial localization of MCC, it is likely that the ER
stress-induced decrease of MCC protein levels may
be mediated through selective mitochondrial autophagy
or proteasome-dependent degradation [57-59]. Together,
our data demonstrated that MCC exhibits a primary
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MCC protein levels are down-regulated by ER stress and
apoptosis induction in malignant B cells. These results
suggest that MCC may play a role in regulating malignant
B cell survival and proliferation.
Lentiviral shRNA vector-mediated knockdown of MCC
induced apoptosis and inhibited proliferation in human
MM cells
Previous studies have shown that MCC blocks cell cycle
progression and inhibits cell proliferation in fibroblasts
and CRCs [20,31,32,35]. To explore the functional roles
of MCC in regulating malignant B cell survival and pro-
liferation, we employed genetic means to manipulate the
expression levels of MCC in human MM cells, including
lentiviral vector-mediated overexpression and knockdown
of MCC, respectively. In contrast to the cell cycle blocking
and proliferation inhibitory effects of MCC overexpression
reported in fibroblasts and CRCs [20,31,32,35], we found
that overexpression of MCC in human MM cell line 8226
cells, which express endogenous MCC at relatively modest
levels, did not affect cell cycle progression, cell prolifera-
tion, or cell survival at all (data not shown). It has been
previously shown that the expression level of ectopically
transfected MCC was strongly reduced in CRCs after sev-
eral passages, suggesting selection against MCC expres-
sion in CRC cultures [35]. However, we observed that
overexpression of MCC was maintained in human MM
8226 cells after >10 passages. Together, the results of our
overexpression studies argue against a negative role for
MCC in the survival or proliferation of malignant B cells.
We next screened four lentiviral shRNA vectors spe-
cific for human MCC using the human MM cell line
LP1 cells. Cells transduced with a scrambled shRNA vec-
tor were used as control in these experiments. Our re-
sults of Western blot analysis showed that the MCC
shRNA 1332 knocked down the protein levels of MCC
by ~85% reduction, while the MCC shRNA 2689 decreased
MCC levels by ~70% reduction in LP1 cells (Figure 4A).
We subsequently used these MCC shRNA lentiviruses to
transduce human MM cell lines LP1 and KMS11 cells. We
found that both MCC shRNAs 1332 and 2689 inhibited
growth and induced apoptosis in human MM cells, as
demonstrated by growth curve determination, trypan blue
or PI staining of dead cells, and annexin V staining of
apoptotic cells (Figure 4B and C). Interestingly, MCC
shRNA 1332 that resulted in a greater decrease in MCC
protein level was also most effective at inducing apoptosis
in human MM cells. In contrast, MCC shRNAs 1388 and
2284, which did not markedly knock down MCC protein
level, did not drastically induce apoptosis in human MM
cells (Figure 4). We further determined whether knock-
down of MCC inhibits the proliferation of human MM
cells by performing cell cycle analysis and proliferationdye labeling experiments. Results of cell cycle analysis
demonstrated that transduction of MCC shRNA 1332 or
2689 resulted in a dramatic decrease in the proliferating
cell population (S/G2/M phase: 2n < DNA content ≤ 4n)
and an increase in the apoptotic cell population (DNA
content < 2n) in human MM cells (Figure 5A). As ob-
served for apoptosis induction, MCC shRNA 1332 was
also more potent than shRNA 2689 in decreasing the pro-
liferating cell population of human MM cells (Figure 5A).
Our results of the proliferation dye labeling experiments
further confirmed that knockdown of MCC by shRNA
1332 remarkably inhibited the proliferation of human
MM cells. This was demonstrated both by the reduction of
GFP+ shRNA 1332-transduced cells and by the slower di-
lution of the proliferation dye in shRNA 1332-transduced
cells as compared to scrambled shRNA-transduced cells
or untransduced cells after culture for 4 days (Figure 5B).
Taken together, our results demonstrate that MCC plays a
positive role and is required for the survival and prolifera-
tion in human MM cells, indicating that MCC acts as an
oncogene in B lymphocytes.
MCC signaling pathways in human MM cells
To understand the mechanisms of MCC shRNA-mediated
induction of apoptosis and inhibition of proliferation in
human MM cells, we investigated the involvement of
known MCC targets. In light of the previous evidence that
MCC specifically targets and negatively regulates the
oncogenic NF-κB and β-catenin pathways in CRCs and
hepatocellular carcinoma [20,27,32,36], we determined the
effects of MCC knockdown on the levels of these two
pathways in human MM cells, including IκBα, IκBβ, RelA,
phospho-β-catenin and β-catenin [20,27,32,36]. Our re-
sults showed that knockdown or overexpression of MCC
did not change any of the proteins of the NF-κB and β-
catenin pathways in human MM cells (Figure 6). We fur-
ther examined another known MCC target involved in
DNA damage response in CRCs, phospho-histone H3 (P-
HH3) [35], which is a marker of mitosis. Contrary to what
was observed in CRCs [35], we found that knockdown of
MCC markedly decreased the level of P-HH3 in human
MM cells, confirming the proliferation-promoting func-
tion of MCC in malignant B cells.
We then measured the levels or activation of a number
of regulators of cell apoptosis and proliferation, includ-
ing caspases, the Bcl-2 family proteins, and cyclins. Our
results demonstrated that knockdown of MCC led to ac-
tivation of both caspases 8 and 3, as evidenced by their
cleavage into active caspase fragments (Figure 6). Inter-
estingly, knockdown of MCC decreased the level of
Mcl1 (an anti-apoptotic protein of the Bcl2 family),
while overexpression of MCC increased the level of
Mcl1 in human MM cells (Figure 6). However, MCC






































































Figure 4 Lentiviral shRNA vector-mediated knockdown of MCC induced apoptosis in human MM cells. The human MM cell line LP1 cells
were transduced with lentiviruses expressing MCC shRNAs (including 1332, 1388, 2284 or 2689) or a scrambled shRNA (Scr). (A) Knockdown of
the MCC protein determined by immunoblot analysis. Total cellular proteins were prepared from LP1 cells successfully transduced with a
scrambled shRNA (Scr), or MCC shRNA 1332, 1388, 2284 or 2689 on day 5 post-transduction. Proteins were immunoblotted for MCC, followed by
actin. Immunoblot of actin was used as a loading control. Results shown are representative of 3 independent experiments, and similar results
were obtained in the human MM cell line KMS11 cells. (B) Growth curves of live cells and percentage of live versus dead cells determined by
Trypan blue-stained cell counting. On day 4 post-transduction, successfully transduced LP1 cells were cultured in a 6-well plate for growth curve
determination. Live and dead cells were counted daily for 4 days using Trypan blue staining and a hemocytometer. The graphs depict the results
of 3 independent experiments (mean ± S.D.). (C) Representative FACS profiles of transduced cells analyzed by annexin V and PI staining. On day 6
post-transduction, transduced LP1 cells were stained with annexin V and PI, and then analyzed by a flow cytometer. In the FACS profiles, apoptotic
cells were identified as annexin V+ PI-, dead cells were annexin V+ PI+, and live cells were annexin V- PI-. Data shown are representative of 3
independent experiments, and similar results were obtained in the human MM cell line KMS11 cells.
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Bcl-xL, Bcl2, Bim, Bad, Bid and Bik (Figure 6). Among
the cell cycle regulators examined, knockdown of MCC
caused specific down-regulation of the protein levels
of cyclin B1 and cyclin A, while overexpression of
MCC increased the level of cyclin B1 in human MM
cells (Figure 6). Knockdown of MCC also led to specificup-regulation of the protein level of the cell cycle inhibi-
tor p27, which was modestly down-regulated by overex-
pression of MCC in human MM cells (Figure 6). In
contrast, MCC knockdown did not change other cell
cycle regulators examined, including cyclin D1, cyclin
D2, p21, E2F1, and p53 (Figure 6). Our findings suggest





















































































































































Figure 5 (See legend on next page.)
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Figure 5 Knockdown of MCC induced apoptosis and inhibited proliferation in human MM cells. (A) Cell cycle distribution analyzed by PI
staining and flow cytometry. The human MM cell line LP1 cells were transduced with lentiviruses expressing MCC shRNAs (1332 or 2689) or a
scrambled shRNA (Scr). Successfully transduced (GFP+) cells were sorted by a FACS sorter on day 4 post-transduction. Top panel shows the FACS
histograms of cells right after sorting (Day 0), and bottom panel shows the FACS histograms of sorted cells after cultured for 24 hours (Day 1).
Gated populations in the FACS histograms indicate apoptotic cells (DNA content < 2n) or proliferating cells (2n < DNA content≤ 4n). Results
shown are representative of 3 independent experiments, and similar results were also obtained in the human MM cell line KMS11 cells. (B) Cell
proliferation analyzed by dilution of the proliferation dye (eFluor 670)-labeling and flow cytometry. On day 4 post transduction, LP1 cells transduced
with MCC shRNA 1332 (1332) or a scrambled shRNA (Scr) were labeled with a proliferation dye eFluor 670, which binds to any cellular protein containing
primary amines. As cells divide, the dye is distributed equally between daughter cells that can be measured as successive halving or dilution of the
fluorescence intensity of the dye. Day 0 FACS profiles and overlay histograms show the eFluor 670 signals of freshly labeled cells, while those of Day 2
and Day 4 show diluted eFluor 670 signals of cells after cultured for 2 and 4 days, respectively. Inhibited proliferation of MCC shRNA 1332-transduced
cells was demonstrated by the hampered dilution of the proliferation dye as compared to those observed in both the untransduced (GFP-) cells and
the scrambled shRNA (Scr)-transduced cells. Results shown are representative of 3 independent experiments with duplicate samples in each
experiment.
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Mcl1 and cyclin B1, and down-regulating p27 in human
MM cells.
To further understand the mechanisms of MCC-
mediated regulation of cell survival and proliferation, we
sought to investigate key signaling pathways that are
known to play important roles in regulating B cell sur-
vival and proliferation, including the activation of p38,
ERK, JNK, Akt and c-Myc [60]. Our results showed that
knockdown of MCC led to specific decreases in the
phosphorylation level of ERK1/2 and the protein level of
c-Myc (a downstream target of ERK), while overexpres-
sion of MCC exhibited the opposite effect in human
MM cells (Figure 6). In contrast, knockdown or overex-
pression of MCC did not change the activation of p38,
JNK and Akt in human MM cells (Figure 6). These results
indicate that ERK-c-Myc is a key signaling pathway under-
lying the oncogenic roles of MCC in malignant B cells.
MCC interacting proteins in human MM cells
To gain further insights into the molecular mechanisms
underlying the oncogenic roles of MCC in B cells, we
set out to identify MCC interacting proteins in human
MM cells. To facilitate co-immunoprecipitation studies,
we constructed two lentiviral expression vectors of
tagged human MCC, including pUB-FLAG-hMCC and
pUB-hMCC-SBP-6×His, which express an N-terminal
FLAG tagged or a C-terminal SBP-6×His tagged MCC,
respectively. We used these vectors to transduce human
patient-derived MM cell line 8226 cells, which express
endogenous MCC at relatively modest levels. Our flow
cytometric data demonstrated that the lentiviral transduc-
tion efficiency by pUB-FLAG-hMCC and pUB-hMCC-
SBP-6×His was > 85% in 8226 cells (data not shown).
Transduced FLAG-hMCC and hMCC-SBP-6×His were
immunoprecipitated from whole cell lysates using anti-
FLAG-agarose or streptavidin-sepharose beads, respect-
ively. We first examined a number of previously known
MCC interacting proteins identified in CRCs or 293Tcells, including β-catenin, Mst3, VCP, PP2A, DFFA, VHL,
VDAC, scribble, and myosin IIb [20,32-34,61]. However,
none of these proteins were detected in co-immunopre-
cipitates with either FLAG-MCC or MCC-SBP-6×His in
human MM cells. Thus, our findings suggest that MCC
inhibits apoptosis and promotes proliferation likely
through interaction with novel, previously unknown part-
ners in malignant B cells.
To delineate the novel MCC-interactome in human
MM cells, we turned to employ an unbiased strategy, af-
finity purification followed by mass spectrometry-based
sequencing. Considering the primary mitochondrial
localization of MCC in human MM cells, immunopre-
cipitates of hMCC-SBP-6×His by streptavidin-sepharose
beads from both whole cell lysates and purified mito-
chondria of 8226 cells were analyzed by high resolution
LC-MS/MS, respectively. In these experiments, immuno-
precipitates of FLAG-hMCC by streptavidin-sepharose
beads were used as negative control. Using this strategy,
we identified 365 proteins in the MCC-interactome of hu-
man MM cells: 333 MCC interacting proteins in whole
cell lysates, and 207 MCC interactors in mitochondria
(Figure 7A, and Additional file 2: Table S2). Among these,
175 MCC interactors were identified in both whole cell ly-
sates and purified mitochondria of human MM cells.
However, only 39 (out of 365, 10.7%) proteins of our study
were also previously identified as MCC interacting pro-
teins in CRCs or 293 T cell (Figure 7A, and Additional
file 2: Table S2) [20,32-34,36,61]. Thus, most of the pro-
teins identified in our study are novel MCC-interacting
partners.
We next performed disease association analyses using
Ingenuity (http://www.ingenuity.com), and cancer is
identified as the top disease associated with the MCC-
interactome identified in our study. Results of Ingenuity
analyses showed that 195 of the 333 (58.5%) MCC inter-
actors in whole cell lysates and 91 of the 207 (43.96%)
MCC interactors in mitochondria are associated with
cancer. Functional annotation and clustering analyses by
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Figure 6 MCC signaling pathways in human MM cells. The human MM cell line LP1 cells, which express high levels of endogenous MCC,
were transduced with lentiviruses expressing MCC shRNA 1332 or a scrambled shRNA (SCR). Another human MM cell line 8226 cells, which
express modest levels of endogenous MCC, were transduced with lentiviruses expressing hMCC (pUB-hMCC) or Thy1.1 only (pUB-Thy1.1). Total
cellular lysates were prepared and immunoblotted for known targets of MCC and regulators of apoptosis or cell cycle. Known target proteins of
MCC examined include phosphorylated β-catenin (P-β-catenin), β-catenin, IκBα, IκBβ, RelA, and phosphorylated histone H3 (P-HH3). Regulators of
apoptosis examined include caspase 8, caspase 3, Bcl-xL, Bcl2, Mcl1, Bim, P-Bad, Bad, Bid, and Bik. Regulators of cell cycle examined include cyclin
D1, cyclin D2, cyclin B1, cyclin A, p21, p27, E2F1, p53, phosphorylated-p38 (P-p38), p38, P-ERK, ERK, P-JNK, JNK, P-Akt, Akt, and c-Myc. The MCC blot
was used as a control for MCC shRNA 1332 or pUB-hMCC transduction, and the actin blot was used as a loading control. Proteins that are changed by
knockdown of MCC are highlighted in blue, and those that are changed by both knockdown and overexpression of MCC are highlighted in red.
Results shown are representative of 3 independent experiments.
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Figure 7 The MCC-interactome in human MM cells identified by affinity purification followed by LC-MS/MS. The human MM cell
line 8226 cells were transduced with lentiviruses expressing hMCC-SBP-6xHis or FLAG-hMCC. Immunoprecipitates of hMCC-SBP-6xHis by
streptavidin-sepharose beads from whole cell lysates and purified mitochondria of 8226 cells were analyzed by high resolution LC-MS/MS,
respectively. Immunoprecipitates of FLAG-hMCC by streptavidin-sepharose beads were used as negative control in these experiments. (A) Venn diagram
of MCC-interactors identified in the present study and previous studies. The diagram depicts the number of previously known MCC-interactors
or MCC-interactors identified in whole cell lysates or mitochondria of human MM cells in our study, as well as the overlap between each
category. (B and C) Functional clustering and annotation of MCC-interactors identified in whole cell lysates (B) or mitochondria (C) of human
MM cells. The number of proteins of each functional cluster is shown. (D) Representative mass spectral profile of a peptide of PHB2 identified
by LC-MS/MS. The deduced peptide sequence is shown. (E) Schematic diagram of peptide sequences of PHB2 identified by LC-MS/MS. The
peptide sequences detected by LC-MS/MS are highlighted in green color.
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are mainly regulators of cell death and survival (81 of
207, 39.1%) (Figure 7B). Similarly, MCC interactors in
whole cell lysates are mainly regulators of cell death and
survival (123 of 333, 36.9%) or cellular growth and pro-
liferation (120 of 333, 36%) (Figure 7C). Other MCCinteractors include regulators of DNA replication and
repair, molecular transport, and protein trafficking
(Figure 7B and C). Together, the MCC-interactome
identified in our study is consistent with the promin-
ent roles of MCC in promoting survival and prolifera-
tion in human MM cells (Figures 4 and 5).
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that differ at their extreme N-terminus due to alternative
promoter usage, isoform 1 (828 amino acids in mouse
and 829 amino acids in human) and isoform 2 (1019
amino acids). The MCC that we cloned from LP1 cells
and used to generate FLAG-hMCC and hMCC-SBP-
6×His is isoform 1 (829 aa). Interestingly, our LC-MS/
MS data identified 6 unique peptides of the isoform 2 of
MCC (1019 aa) in the immunoprecipitates of hMCC-
SBP-6×His in both whole cell lysates and purified mito-
chondria (Additional file 3: Figure S1 and Additional file 2:
Table S2). These results demonstrate that the two iso-
forms of MCC form hetero-dimers or hetero-oligomers in
human MM cells.
From the top 10 MCC-interactors identified in both
whole cell lysates and purified mitochondria of human
MM cells, we selected to further verify the interaction of
MCC with two important regulators of cell survival and
proliferation, PARP1 and prohibitin-2 (PHB2, Figure 7D
and E) [62-65], by co-immunoprecipitation and Western
blot analyses. Our results confirmed the interactions of
MCC with PARP1 and PHB2 in both whole cell lysates
and purified mitochondria of human MM cells (Figure 8A
and B). We further performed an interaction network ana-
lysis using the top 100 MCC-interactors of human MM
cells (60 proteins identified in both whole cell lysates and
mitochondria, 10 proteins identified in mitochondria only,
and 30 proteins identified in whole cell lysates only) and
the STRING analysis tool (http://www.string-db.org) [66],
which builds protein interaction networks based on
known and predicted protein-protein interactions. As
shown in Figure 8C, 61 proteins of the top 100 MCC-
interactors form an interaction network centered upon
PARP1 and PHB2. Interestingly, PARP1 and PHB2 have
also been previously shown to directly or indirectly inter-
act with and/or regulate MCC targets identified by knock-
down and overexpression of MCC studies in human MM
cells (Figure 6), including ERK, c-Myc, p27, cyclin B1,
Mcl-1, caspase 8, and caspase 3 [62-65]. Taken together,
our findings indicate that MCC promotes cellular survival
and proliferation by associating with and modulating the
interaction network centered at PARP1 and PHB2 in ma-
lignant B cells.
Discussion
The late onset and long latency of lymphoma develop-
ment observed in B-TRAF3-/- mice suggest that second-
ary oncogenic hits are required to promote B cell
transformation. In the present study, we identified MCC
as a gene strikingly up-regulated in TRAF3−/− mouse B
lymphomas and human MM cell lines. Aberrant expres-
sion of MCC has also been documented in primary hu-
man B cell malignancies, including PEL, CBL, DLBCL,
BL, and MM [38-41]. In contrast, MCC expression wasnot detected in normal or premalignant TRAF3−/− B
cells even after treatment with B cell stimuli, suggesting
that aberrant expression of MCC is specifically associ-
ated with malignant transformation of B cells. In eluci-
dating the function of MCC in malignant B cells, we
found that lentiviral shRNA-mediated knockdown of
MCC induced apoptosis and inhibited proliferation in
human MM cells. Experiments of knockdown and over-
expression of MCC allowed us to identify downstream
targets of MCC in human MM cells, including ERK, c-
Myc, p27, cyclin B1, Mcl-1, caspase 8, and caspase 3.
Furthermore, we delineated the profile of proteins as-
sembled in the MCC signaling complex in whole cells or
mitochondria by employing affinity purification followed
by mass spectrometry-based sequencing. Our results in-
dicate that MCC associates with the interaction network
centered upon PARP1 and PHB2 to promote cellular
survival and proliferation in malignant B cells. Collect-
ively, our findings indicate that MCC functions as an
oncogene in B cells.
Paradoxically, in contrary to the up-regulation of MCC
in B cell neoplasms, the MCC gene is frequently deleted,
mutated, or silenced in other human cancers, including
colorectal cancer [14-17,19,20,22], lung cancer [17,23],
gastric carcinoma [24], esophageal cancer [25], and he-
patocellular carcinoma [26,27]. Functional evidence and
signaling pathway studies indicate that MCC acts as a
tumor suppressor gene by inhibiting the oncogenic NF-κB
and β-catenin pathways in CRCs and hepatocellular
carcinoma [20,27,31-36]. We also previously observed
regulation of β-catenin by Sox5, another gene identified in
our microarray analysis, in human MM cells [67]. How-
ever, NF-κB and β-catenin levels were not altered by
knockdown or overexpression of MCC in human MM
cells. Thus, MCC plays distinct roles via different signaling
mechanisms in B cell malignancies versus other human
cancers.
It has been shown that in CRCs, MCC mainly localizes
in the cytoplasm, and is induced to shuttle into the nu-
cleus in response to DNA damage [35]. Interestingly, we
found that MCC is primarily localized at mitochondria,
but also detectable in the ER, cytosol and nucleus in hu-
man MM cells. MCC does not contain any mitochon-
drial targeting motifs or transmembrane domains.
Through delineation of the mitochondrial MCC-
interactome, we identified a number of mitochondrial
proteins that are associated with MCC in human MM
cells, including PHB2, prohibitin (PHB), ECHA, VDAC3,
ADT1, ADT2, and ADT3. All of these mitochondrial
proteins are known as critical regulators of cell survival
and apoptosis (http://www.ingenuity.com). Therefore,
MCC is primarily localized at mitochondria to promote
cellular survival by interacting with multiple mitochon-











































































Figure 8 (See legend on next page.)
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Figure 8 PARP1 and PHB2 are two hubs of the MCC interaction network in human MM cells. The human MM cell line 8226 cells were
transduced with pUB-hMCC-SBP-6xHis or pUB-FLAG-hMCC. Immunoprecipitation was performed as described in Figure 7. (A and B) Immunoblot
analyses of proteins pulled down by streptavidin-sepharose beads (SA IP) from whole cell lysates (A) or purified mitochondria (B). Proteins were
immunoblotted for PARP1, PHB2, SBP, and followed by MCC. Blots of an aliquot of whole cell or mitochondrial lysates before immunoprecipitation
were used as the input control. (C) The MCC interaction network in human MM cells. We performed an interaction network analysis using the top 100
MCC-interactors and the STRING analysis tool (http://www.string-db.org). The top 100 MCC-interactors identified in our study and used for the
interaction network analysis include 60 proteins identified in both whole cell lysates and mitochondria, 10 proteins identified in mitochondria only,
and 30 proteins identified in whole cell lysates only. Sixty-one proteins of the top 100 MCC-interactors of human MM cells form an interaction network
centered at PARP1 and PHB2.
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interactome identified in our study are novel, previously
unknown MCC-interacting partners. Among these,
PARP1 is the top novel MCC-interactor identified in
both mitochondrial and whole cell lysates of human
MM cells. PARP1, the most abundant member of the
polyADP-ribose polymerases (PARP) family, catalyzes
post-translational modification of proteins by polyADP-
ribosylation. This modification affects protein-protein
and protein-DNA interactions. In addition to its pivotal
role in DNA repair, PARP1 also critically regulates tran-
scription, cell survival, and proliferation [62,63]. PARP1
can act in both a pro- and anti-tumor manner de-
pending on the context [62]. In this study, we identified
PARP1 as a signaling hub of the MCC-interactome
in human MM cells (Figure 8C). PARP1 is known to
interact with numerous MCC interactors identified in
our study, including CDK1, MCM4, XRCC6, RFC1,
CCT2, SSRP1, TOP2B, HIST1H1C, and SUPT16H (http://
www.string-db.org). Interestingly, PARP1 has been shown
to directly or indirectly regulate the activation or expres-
sion of multiple MCC targets identified by our knock-
down and overexpression experiments, including caspase
8, ERK, c-Myc, p27, cyclin B1, and Mcl1 (Figure 6). In-
deed, PARP1 can induce the PARylation of caspase-8,
thereby inactivating caspase-8 and inhibiting caspase-
mediated apoptotic signaling [62]. PARP1 directly interacts
with phosphorylated ERK2 to mediate cell proliferation,
whereas PARP1 inhibition causes loss of ERK2 stimula-
tion [62,63]. PARP1 also down-regulates the expression
of MKP-1, which dephosphorylates ERK [62]. Through
modifications of chromatin or interactions with gene
specific promoters/transcription factors, PARP1 regu-
lates in total 3.5% of the transcriptome, including in-
creasing the expression of c-Myc [62,63] and repressing
the expression of p27 [68]. Furthermore, PARP1 can in-
directly regulate the degradation and anti-apoptotic
function of Mcl1 through interaction with CDK1/cyclin
B1 [69,70]. Therefore, PARP1 is a novel MCC-interactor
that plays a central role in mediating the oncogenic ef-
fects of MCC in malignant B cells.
Thirty-nine proteins of the MCC-interactome identi-
fied in our study are previously known as MCC-
interacting proteins in CRCs or 293T cells. Among these,PHB2 is the top known MCC-interactor identified in
both mitochondrial and whole cell lysates of human
MM cells. PHB2, a ubiquitously expressed pleiotropic
protein, is mainly localized in mitochondria by forming
heteromeric complex with PHB, but also present in the
cytosol, nucleus and plasma membrane [64,65,71]. PHB2
plays crucial roles in regulating mitochondrial function,
cell survival, proliferation, stress response, and develop-
ment [64,65,71]. PHB2 is expressed at higher levels in
proliferating cells, including neoplastic tissues [64,65,71].
Silencing or abrogation of PHB2 induces apoptosis
and reduces proliferation in a variety of cancer cells
[64,65,71]. Here we identified PHB2 as another hub of
the MCC interaction network in human MM cells
(Figure 8C). Previous studies have demonstrated the as-
sociation between PHB2 and multiple MCC-interactors
identified in our study, including PHB, CSNK1D (CK1δ),
CSNK1E (CK1ε), ATP5B, NUMA1, and SLC25A6
(http://www.string-db.org) [65,72]. PHB2 has also been
shown to directly or indirectly regulate the activity or
expression of multiple MCC targets identified in our
study, including caspase 3, ERK, c-Myc, p27, and cyclin
B1 (Figure 6). For example, over-expression of PHB2 in-
hibits caspase 3 activation and cell apoptosis, whereas
down-regulation of PHB2 is associated with increased
caspase 3 expression and cell apoptosis [64,65,71]. PHB
and PHB2 interact with c-Raf to induce the phosphoryl-
ation of ERK1/2 via MEK1 [65]. Through activation of
ERK1/2, PHB2 may also indirectly regulate the expres-
sion levels of downstream targets of the ERK pathway,
including c-Myc, p27 and cyclin B1 [65,71,73,74]. The c-
Myc up-regulation mediated by MCC-PHB2 or MCC-
PARP1 via ERK signaling pathway in MM cells is
functionally analogous to that induced by canonical
Wnt-β-catenin signal activation observed in epithelial
cells [75,76]. Thus, similar to PARP1, PHB2 and PHB
are likely to play essential roles in mediating the onco-
genic effects of MCC in malignant B cells.
Interestingly, preclinical evidence indicates that both
PARP1 and PHB2/PHB are excellent therapeutic targets
in cancer [62,65]. In preclinical studies, PARP inhibitors
(such as olaparib) exhibit potent tumoricidal activities
on breast cancer, ovarian cancer, pancreatic cancer, pros-
tate cancer, Ewing’s sarcoma, small cell lung carcinoma,
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fects of olaparib on BRCA-mutated breast cancer have
been confirmed in early phase clinical trials with only
mild adverse side effects [62]. Notably, PHB ligands
(such as flavaglines and capsaicin) display robust cyto-
toxicity on cancer cells, but have cytoprotective activities
on normal cells (e.g. neurons and cardiomyocytes), par-
ticularly against oxidative stress [65]. PHB and PHB2
were recently identified as the direct targets of flava-
glines (e.g., rocaglamide, rocaglaol and silvestrol), natural
products isolated from medicinal plants that show sig-
nificant anticancer effects but no sign of toxicity in mice
[65]. Capsaicin, a component of hot chili peppers, binds
to PHB2, and this binding induces apoptosis in human
myeloid leukemia cells [65]. Both flavaglines and capsa-
icin regulate subcellular localization of PHB2 [77-79].
Flavaglines specifically inhibit PHB1/2-c-Raf interaction
and prevent PHB1/2-c-Raf membrane localization [79],
while capsaicin induces the translocation of PHB2 from
mitochondria to the nucleus [77,78]. Such specific tar-
geting mechanisms of PHB ligands suggest that they
may exert robust synergistic effects with conventional
chemotherapies that target different signaling pathways,
including DNA damage response, proteasome, the Bcl-2
family, and NF-κB activation. In this regard, flavaglines
have been shown to enhance the efficacy of doxorubicin
in mouse lymphoma models [65]. Therefore, identifica-
tion of PARP1 and PHB2/PHB as hubs of the signaling
pathways of MCC in human MM cells implicates poten-
tial use of PARP inhibitors and PHB ligands in the treat-
ment of B cell malignancies involving aberrant expression
of MCC.
Conclusions
In the present study, we have identified MCC as a novel
oncogene in B lymphocytes and provided insights into
its signaling mechanisms in human MM cells. In the
unique cellular context of malignant B cells, MCC forms
an interaction network centered at PARP1 and PHB2 to
promote cellular survival and proliferation by up-
regulating ERK activation, c-Myc, Mcl1, and cyclin B1,
and by down-regulating p27 and suppressing cleavage of
caspases 8 and 3. The lack of expression of MCC in
normal or premalignant B cells but ubiquitous up-
regulation of MCC in primary human B cell malignances
suggests that MCC may be a useful diagnostic marker
for B cell neoplasms. Our finding that knockdown of
MCC induced apoptosis and inhibited proliferation in
human MM cells suggests that MCC may also serve as a
therapeutic target in B cell malignancies. Furthermore,
the central role of PARP1 and PHB2 in the MCC inter-
action network of human MM cells implies that PARP1
inhibitors and PHB ligands may have therapeutic appli-
cation in B cell neoplasms, including NHL and MM.Methods
Mice, cell lines, and reagents
Mice and disease monitoring were as previously de-
scribed [12,13]. Human patient-derived MM cell lines
were generously provided by Dr. Leif Bergsagel (Mayo
Clinic, Scottsdale, AZ), including 8226, KMS11, LP1,
U266, KMS28PE, and KMS20. The EBV-transformed
human B lymphoblastoid cell line C3688 was provided
by Dr. Lori Covey (Rutgers University, Piscataway, NJ).
All human B cell lines were cultured as described [80].
Most antibodies and reagents used in this study were as
previously described [13,67,80]. Mouse monoclonal Abs
to MCC were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). DTT, thapsigargin, and lentiviral
shRNA constructs for human MCC were purchased
from Sigma-Aldrich Corp. (St. Louis, MO). The plasmid
pENTR1A-NTAP-A containing the SBP tag sequence
was purchased from Addgene (Cambridge, MA). PARP1
Abs were from eBioscience (San Diego, CA), and PHB2
Abs were purchased from Bethyl Laboratories Inc
(Montgomery, TX). Additional polyclonal rabbit Abs
were from Cell Signaling Technology (Beverly, MA).
Transcriptome microarray analysis
Total RNA was extracted from splenocytes of LMC
(mouse ID: 6983–6, 7041–9, and 7060–5) and tumor-
bearing B-TRAF3−/− mice (mouse ID: 6983–2, 7041–10,
and 7060–8) using TRIzol reagent (Invitrogen, Carlsbad,
CA) following the manufacturer’s instructions. RNA
quality was assessed on an RNA Nano Chip using an
Agilent 2100 Bioanalyzer (Agilent Technologies, Palo
Alto, CA). The mRNA was amplified with a TotalPrep
RNA amplification kit with a T7-oligo(dT) primer accord-
ing to the manufacturer’s instructions (Ambion), and
microarray analysis was carried out with the Illumina Sen-
trix MouseRef-8 24 K Array at the Burnham Institute (La
Jolla, CA). Results were extracted with Illumina Geno-
meStudio v2011.1, background corrected and variance sta-
bilized in R/Bioconductor using the lumi package [81,82]
and modeled in the limma package [83]. Microarray data
are available from NIH GEO Accession GSE48818.
Taqman assays of the transcript expression of identified
genes
Complementary DNA (cDNA) was prepared from RNA
using High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems, Carlsbad, CA). Quantitative real-
time PCR of specific genes was performed using corre-
sponding TaqMan Gene Assay kit (Applied Biosystems) as
previously described [84]. Briefly, real-time PCR was per-
formed using TaqMan primers and probes (FAM-labeled)
specific for mouse MCC, Diras2, Tbc1d9, Ccbp2, Btbd14a,
Sema7a, Twsg1, Ppap2b, TCF4, Tnfrsf19, Zcwpw1, Abca3,
or human MCC. Each reaction also included the probe
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mRNA, which served as an endogenous control. Relative
mRNA expression levels of each gene were analyzed using
the Sequencing Detection Software (Applied Biosystems)
and the comparative Ct method (ΔΔCt) as previously de-
scribed [84].
Splenic B cell purification and stimulation
Splenic B cells were purified using anti-mouse CD43-
coated magnetic beads and a MACS separator (Miltenyi
Biotec Inc.) following the manufacturer’s protocols as
previously described [12,84]. The purity of isolated pop-
ulations was monitored by FACS analysis, and cell prep-
arations of >95% purity were used for RNA and protein
extraction. Purified B cells were cultured ex vivo in the
absence or presence of B cell stimuli for 6 or 24 hours
as described previously [12,84]. B cell stimuli examined
include 2 μg/ml anti-CD40, 20 μg/ml LPS, 1 μg/ml anti-
BCR, and 100 nM CpG2084, alone or in combination.
Total cellular RNA was prepared at 6 or 24 hours after
stimulation.
Taqman copy number assay of the mouse MCC gene
Genomic DNA was prepared from splenocytes of LMC
and tumor-bearing B-TRAF3−/− mice as previously de-
scribed [13]. Quantitative real-time PCR of the mouse
MCC gene was performed using the TaqMan Copy
Number Assay kit (assay ID: Mm00490037_cn; Applied
Biosystems) following the manufacturer’s protocols.
Briefly, real-time PCR was performed using the TaqMan
primers and probe (FAM-labeled) specific for the mouse
MCC gene. Each reaction also included the probe (VIC-
labeled) and primers specific for the mouse Trfc gene
(TaqMan Copy Number Reference Assay, Applied Bio-
systems), which served as reference control. Relative
copy numbers of the MCC gene in genomic DNA sam-
ples were analyzed using the Sequencing Detection Soft-
ware (Applied Biosystems) and the comparative Ct
method (ΔΔCt) following the manufacturer’s protocols.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) assays were
performed essentially as described previously [85,86].
Briefly, 20 × 106 cell equivalents of fragmented chroma-
tins (containing DNA fragments < 400 bp) were immu-
noprecipitated with Ig isotype control or antibodies
specific for histone modifications. We used the following
histone antibodies in the ChIP experiments: H3K27me3
(Millipore, Billerica, MA) and H3K9/14ac (Diagenode,
Denville, NJ). Immunoprecipitated DNA were purified,
and then analyzed by quantitative real time PCR using
primers specific for the promoter region of the mouse
MCC or Diras2 gene. Primer used are: mMCC-U519F
(5’- CAG GGA GGT TGG AGA GGA -3’) and mMCC-U446R (5’- AAA CAT GCC CTG CCC TTG -3’);
mDiras2-U559F (5’- GCA CAT GTG ACT ACT ATT
G -3’) and mDiras2-U480R (5’- AAT CTC TCC TCC
CAC AAG -3’). The enrichments of each gene promoter
immunoprecipitated by histone marks were quantitated
relative to the input DNA [86].
Cloning of the full-length cDNA of the MCC gene from
TRAF3−/− mouse B lymphomas and human MM cell lines
Total cellular RNA was prepared from B lymphomas
spontaneously developed in four individual B-TRAF3−/−
mice (mouse ID: 6983–2, 7060–8, 105–8, and 115–6),
and the corresponding cDNA samples were used as tem-
plates to clone the mouse MCC coding sequences using
primers mMCC-F (5’- ATG AAT TCT GGA GTT GCG
GTG -3’) and mMCC-R (5’- TTA GAG TGA CGT TTC
GTT GGT G -3’). Similarly, human MCC coding se-
quences were cloned from human MM cell lines LP1
and KMS11 cells using reverse transcription PCR.
Primers used for the cloning of human MCC are
hMCC-F (5’- TGC ATC ATG AAT TCC GGA GT -3’),
and hMCC-R (5’- TTA AAG CGA AGT TTC ATT
GGT GTG -3’). The high fidelity polymerase Pfu UltraII
(Santa Clara, CA) was used in these PCR reactions. Se-
quences of the cloned mouse and human MCC were de-
termined at GenScript (Piscataway, NJ).
Generation of lentiviral MCC expression and shRNA vectors
The coding cDNA sequence of MCC cloned from the
human MM cell line LP1 cells was subcloned into the
lentiviral expression vector pUB-eGFP-Thy1.1 [87] (gen-
erously provided by Dr. Zhibin Chen, the University of
Miami, Miami, FL) by replacing the eGFP coding se-
quence with the MCC coding sequence. To facilitate
immunoprecipitation experiments, we engineered an N-
terminal FLAG tag or a C-terminal SBP-6×His tag [88]
in frame with the MCC coding sequence, respectively.
We subsequently generated two lentiviral expression
vectors of tagged hMCC, including pUB-FLAG-hMCC
and pUB-hMCC-SBP-6×His. Lentiviral shRNA vectors
specific for human MCC (including hMCC shRNA 1332,
1388, 2284 and 2689; all in Torc1 vectors) or a scram-
bled shRNA vector were purchased from Sigma. To fa-
cilitate FACS analysis and cell sorting, we engineered an
eGFP-expressing version of all the shRNA vectors by re-
placing the puromycin resistance gene of Torc1 with the
eGFP coding sequence. Each lentiviral expression or
shRNA vector was verified by DNA sequencing.
Lentiviral packaging and transduction of human MM cells
Lentiviruses of MCC shRNA vectors and a scrambled
shRNA vector were packaged following the manufac-
turer’s protocol (Sigma) as previously described [13,89].
Lentiviruses of MCC expression vectors were packaged
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MM cells were transduced with the packaged lentivi-
ruses at a MOI of 1:5 (cell:virus) in the presence of 8 μg/
ml polybrene [13,87,89]. Transduction efficiency of cells
was analyzed by flow cytometry on day 3 post transduc-
tion. All shRNA vectors contain an eGFP expression cas-
sette, and were directly analyzed using a flow cytometer.
All pUB lentiviral expression vectors have an expression
cassette of the marker Thy1.1, and thus allow the trans-
duced cells to be analyzed by Thy1.1 immunofluores-
cence staining followed by flow cytometry. Transduced
cells were subsequently sorted or directly analyzed for
apoptosis, cell cycle distribution, proliferation, and pro-
tein expression.
Growth curve determination, annexin V staining of
apoptotic cells, cell cycle distribution, and cell
proliferation analyses
For MCC knockdown studies, on day 4 post-transduction,
successfully transduced cells were sorted for GFP+ shRNA
expressing populations, and then plated in 6-well plates
for growth curve determination, annexin V staining, or
cell cycle analysis. For growth curve determination, live
and dead cells were differentiated using trypan blue stain-
ing, and counted using a hemacytometer. For analysis of
apoptosis, cells were stained with annexin V and PI ac-
cording to the manufacturer’s protocol (Invitrogen), and
analyzed by flow cytometry as previously described [13].
For cell cycle analysis, cells were fixed with ice-cold 70%
ethanol. Cell cycle distribution was subsequently deter-
mined by propidium iodide (PI) staining followed by flow
cytometry as previously described [12,90]. For cell prolif-
eration analysis, cells were labeled with a cell proliferation
dye eFluor® 670 (eBioscience), and dilution of the prolifer-
ation dye was analyzed by flow cytometry following the
manufacturer’s protocol.
Total protein lysates, fractionation of cytosol,
mitochondria and microsomes (rich in ER), and
immunoblot analysis
For total protein lysates, cell pellets were lysed in 200 μl
of 2X SDS sample buffer (0.0625 M Tris, pH6.8, 1%
SDS, 15% glycerol, 2% β-mercaptoethanol and 0.005%
bromophenol blue), sonicated for 30 pulses, and boiled
for 10 minutes.
For biochemical fractionation, human MM cells (30 ×
106 cells/condition) were cultured in the absence or
presence of 250 μM DTT or 0.5 μM thapsigargin for
24 hours. Cytosol, mitochondria and microsomes (rich
in ER) were fractionated from cells as previously de-
scribed [91-93]. Briefly, cells were washed with ice-cold
PBS, swelled in 700 μl of Mitochondria Isolation Buffer
(250 mM sucrose, 10 mM HEPES, pH7.5, 10 mM KCl,
1 mM EDTA, and 0.1 mM EGTA with protease andphosphatase inhibitors) on ice for 10 minutes, and then
homogenized in a Dounce homogenizer. Cell lysis was
checked by trypan blue uptake, and homogenization
stopped when 90% of cells were broken. Nuclei were pel-
leted by centrifugation at 1,000 g for 10 minutes at 4°C.
The cleared lysates were then centrifuged at 10,000 g for
25 minutes at 4°C to obtain the pellets of mitochondria.
The supernatants were further centrifuged at 100,000 g
for 2 hours to separate the pellets of microsomes (rich in
ER) from cytosolic proteins (S100 fraction). One-fifth vol-
ume of 5X SDS sample buffer was added into each S100
fraction. The pellets of nuclei, mitochondria and micro-
somes (rich in ER) were lysed and sonicated in 300 μl of
2X SDS sample buffer, respectively. All protein samples
were subsequently boiled for 10 minutes.
Total protein lysates, or cytosolic, ER, mitochondrial
and nuclear proteins were separated by SDS-PAGE.
Immunoblot analyses were performed using specific anti-
bodies as previously described [67,80]. Images of immuno-
blots were acquired using a low-light imaging system
(LAS-4000 mini, FUJIFILM Medical Systems USA, Inc.,
Stamford, CT).
Co-immunoprecipitation assay in whole cell lysates
Human MM cell line 8226 cells (5 × 107 cells/condition)
transduced with pUB-FLAG-hMCC or pUB-hMCC-
SBP-6×His were lysed and sonicated in the CHAPS lysis
buffer [94] (1% CHAPS, 20 mM Tris, pH 7.4, 150 mM
NaCl, 50 mM β-glycerophosphate, and 5% glycerol with
freshly added 1 mM DTT and EDTA-free Mini-complete
protease inhibitor cocktail). The insoluble pellets were
removed by centrifugation at 10,000 g for 20 minutes at
4°C. The CHAPS lysates were subsequently immunopre-
cipitated with anti-FLAG-agarose beads (Sigma; for
FLAG-hMCC), or streptavidin-sepharose beads (Pierce,
Rockford, IL; for hMCC-SBP-6×His), separately. Immu-
noprecipitates were washed 5 times with the Wash Buf-
fer (0.5% CHAPS, 20 mM Tris, pH 7.4, 150 mM NaCl,
50 mM β-glycerophosphate, and 2.5% glycerol with
freshly added 1 mM DTT and EDTA-free Mini-complete
protease inhibitor cocktail). Immunoprecipitated pro-
teins were resuspended in 2× SDS sample buffer, boiled
for 10 minutes, and then separated on SDS-PAGE for
mass spectrometry or immunoblot analyses.
Co-immunoprecipitation assay in mitochondrial lysates
Human MM cell line 8226 cells (1.5 × 108 cells/condi-
tion) transduced with pUB-FLAG-hMCC or pUB-
hMCC-SBP-6×His were used for cytosol, mitochondria
and ER fractionation as described above. Mitochondrial
pellets were lysed and sonicated in the CHAPS lysis buf-
fer [94], and cleared by centrifugation at 10,000 g for
20 minutes at 4°C. The mitochondrial lysates were subse-
quently immunoprecipitated with streptavidin-sepharose
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munoprecipitates were washed 5 times with the Wash
Buffer, resuspended in 2× SDS sample buffer, boiled for
10 minutes, and then separated on SDS-PAGE for mass
spectrometry or immunoblot analyses.
Mass spectrometry based-sequencing
Whole cell lysates or mitochondrial lysates immunopre-
cipitated with streptavidin-sepharose beads were used
for LC-MS/MS. The entire gel lanes for hMCC-SBP-
6×His complex and negative control (FLAG-hMCC)
were each sectioned into 15 continuous slices. The gel
slice samples were subjected to thiol reduction by TCEP,
alkylation with iodoacetamide, and digestion with
sequencing-grade modified trypsin [95,96]. Peptides
were eluted from the gel slices, desalted, and then sub-
jected to reversed-phase nano-flow ultra high perform-
ance capillary liquid chromatography (uPLC) followed
by high-resolution/high-mass accuracy MS/MS analysis
using an LC-MS platform consisting of an Eksigent
Nano Ultra 2D Plus uPLC system hyphenated to a
Thermo Orbi Velos mass spectrometer. The MS/MS
was set to operate in data dependent acquisition mode
using a duty cycle in which the top 15 most abundant
peptide ions in the full scan MS were targeted for MS/
MS sequencing. Full scan MS1 spectra were acquired at
100,000 resolving power and maintained mass calibra-
tion to within 2–3 ppm mass accuracy. LC-MS/MS data
were searched against the human IPI and UniProt data-
bases using the Mascot and Proteome Discoverer search
engines [95,96]. Protein assignments were considered
highly confident using a stringent false discovery rate
threshold of <1%, as estimated by reversed database
searching, and requiring that ≥2 peptides per protein be
unambiguously identified. Rough relative protein amounts
were estimated using spectra counting values.
Statistics
Statistical analyses were performed using the Prism soft-
ware (GraphPad, La Jolla, CA). Statistical significance
was assessed by Student t test. P values less than 0.05
are considered significant.
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